Collegium Pharmaceutical, Inc. Share Price & Technical Analysis
COLL · $33.78 (-0.85%)
Healthcare / Drug Manufacturers - Specialty & Generic
$33.78
-0.85%
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine …
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
1% return in May, -2% avg return in past 3 year May month.
-29% return in 2026, 30% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -1% | -9% | -21% | 1% | 1% | – | – | – | – | – | – | – | -29% |
| 25 | 11% | -8% | 3% | -10% | 9% | 1% | 1% | 30% | -10% | 3% | 30% | -1% | 59% |
| 24 | 7% | 11% | 5% | -4% | -11% | -2% | 19% | -1% | 1% | -12% | -11% | -6% | -3% |
| 23 | 20% | -6% | -10% | -3% | -4% | -2% | 6% | 4% | -5% | -2% | 17% | 20% | 35% |
| 22 | -4% | 10% | 6% | -21% | -3% | 13% | -1% | 4% | -8% | 11% | 20% | 6% | 32% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Downtrend · Neutral
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. Collegium Pharmaceutical, Inc. was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. The company was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$1.16B
P/E ratio
17.42
52W high
$50.79
52W low
$28.73
Volume
2,74,695
Beta
0.76
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Collegium Pharmaceutical, Inc. share price today?
- Collegium Pharmaceutical, Inc. (COLL) last traded around $33.78 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does COLL have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for COLL. Download the app for real-time alerts.
- How can I analyze Collegium Pharmaceutical, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.